Clinical Trials Browser

Phase 3 × Myeloproliferative Disorders × 1 year × Clear all

Myeloproliferative Disorders, Primary Myelofibrosis

NCT01366612 2026-04-03

FLUBUTBI

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT03480360 2026-02-19

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Phase 3 Active not recruiting

21 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Lymphoma, Lymphoma, Non-Hodgkin, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell, Primary Myelofibrosis

Clinical Trials

SENTRY

FLUBUTBI

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

ASC4START

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

APHYPAP

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

FREEDOM2

SURPASS ET

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

INDEPENDENCE